IFNG and neoplasm: A total of 11 of the 15 evaluable patients (73.3%; 9 of 11 evaluable patients from group I and group III and 2 of 4 evaluable patients from group II) displayed an elevated frequency of tumor-specific IFN-γ-producing CTLs in peripheral blood after vaccination.